Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results of an international randomized, double-blind, placebo-controlled trial

European Urology

Volumn 60, Issue 5, 2011, Pages 1105-1113

  Porst, Hartmut ^a   Kim, Edward D ^b   Casabé, Adolfo R ^c   Mirone, Vincenzo ^d   Secrest, Roberta J ^e   Xu, Lei ^e   Sundin, David P ^e   Viktrup, Lars ^e  

^a Private Practice of Urology and Andrology   (Germany)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^c Specialized Medical Institute   (Argentina)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Benign prostatic hyperplasia; Erectile dysfunction; Lower urinary tract symptoms; Phosphodiesterase type 5 inhibitors; Tadalafil

Indexed keywords

PLACEBO; TADALAFIL;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BACKACHE; BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCARDITIS; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION ERECTILE FUNCTION SCORE; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; URINE FLOW RATE;

AGED; ANALYSIS OF VARIANCE; ARGENTINA; CARBOLINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPE; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MEXICO; MIDDLE AGED; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; PLACEBOS; PROSTATIC HYPERPLASIA; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; URINATION; URODYNAMICS;

EID: 80053308004     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.08.005     Document Type: Article

References (35)

1. C. Chapple Medical treatment for benign prostatic hyperplasia BMJ 304 1992 1198 1199
2. Guideline on the management of benign prostatic hyperplasia (BPH). American Urological Association Web site. http://www.auanet.org/content/ guidelines-and-quality-care/clinical-guidelines/main-reports/bph-management/ chap-1-GuidelineManagementof(BPH).pdf. Updated 2010. Accessed July 2011.
3. Guidelines on benign prostatic hyperplasia. European Association of Urology Web site. http://www.uroweb.org/gls/pockets/english/ 11%20Benign%20Prostatic%20Hyperplasia.pdf. Updated March 2005. Accessed July 2011.
4. H. Hashim, and P. Abrams Emerging drugs for the treatment of benign prostatic obstruction Expert Opin Emerging Drugs 15 2010 159 174
5. P. Abrams, L. Cardozo, and M. Fall Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society Urology 61 2003 37 49 (Pubitemid 36151708)
6. C.G. Roehrborn, P. Siami, and J. Barkin The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol 57 2010 123 131
7. K.T. McVary, W. Monnig, J.L. Camps Jr., J.M. Young, L.J. Tseng, and E.G. van den Ende Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 2007 1071 1077 (Pubitemid 46216352)
8. C.G. Roehrborn, K.T. McVary, A. Elion-Mboussa, and L. Viktrup Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study J Urol 180 2008 1228 1234
9. C.G. Stief, H. Porst, D. Neuser, M. Beneke, and E. Ulbrich A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 2008 1236 1244
10. R. Dmochowski, C. Roehrborn, S. Klise, L. Xu, J. Kaminetsky, and S. Kraus Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial J Urol 183 2010 1092 1097
11. K.E. Andersson, S. Uckert, C. Stief, and P. Hedlund Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS Neurourol Urodyn 26 Suppl 6 2007 928 933 (Pubitemid 47548230)
12. K.E. Andersson, W.C. de Groat, and K.T. McVary Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action Neurourol Urodyn 30 2011 292 301
13. S. Uckert, M. Oelke, C.G. Stief, K.E. Andersson, U. Jonas, and P. Hedlund Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate Eur Urol 49 2006 740 745 (Pubitemid 43374744)
14. S.T. Forgue, B.E. Patterson, and A.W. Bedding Tadalafil pharmacokinetics in healthy subjects Br J Clin Pharmacol 61 2006 280 288 (Pubitemid 43382627)
15. Cialis (tadalafil) tablets. US Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021368s017lbl.pdf. Updated February 2010. Accessed July 2011.
16. Cialis 2.5 mg, 5 mg, 10 mg & 20 mg film-coated tablets. UK summary of product characteristics. Electronic Medicines Compendium Web site. http://www.medicines.org.uk/EMC/medicine/11363/SPC/Cialis. Updated March 2011. Accessed July 2011.
17. K.T. McVary, C.G. Roehrborn, and J.C. Kaminetsky Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 177 2007 1401 1407 (Pubitemid 46435965)
18. M.J. Barry, J. Fowler, and M.P. O'Leary The American Urological Association symptom index for benign prostatic hyperplasia J Urol 148 1992 1549 1557
19. R.C. Rosen, A. Riley, G. Wagner, I.H. Osterloh, J. Kirkpatrick, and A. Mishra The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction Urology 49 1997 822 830 (Pubitemid 27246947)
20. M.J. Barry, J. Fowler, M.P. O'Leary, R.C. Bruskewitz, H.L. Holtgrewe, and W.K. Mebust Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association Medical Care 33 Suppl 4 1995 AS145 AS155
21. R.C. Bump, P.A. Norton, N.R. Zinner, I. Yalcin Duloxetine Urinary Incontinence Study Group Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response Obstet Gynecol 102 2003 76 83 (Pubitemid 36792126)
22. Guy W, editor. ECDEU assessment manual of psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare: Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
23. I. Yalcin, and R.C. Bump Validation of two global impression questionnaires for incontinence Am J Obstet Gynecol 189 2003 98 101 (Pubitemid 36886531)
24. I. Yalcin, and L. Viktrup Comparison of physician and patient assessments of incontinence severity and improvement Int Urogynecol J Pelvic Floor Dysfunc 18 2007 1291 1295 (Pubitemid 47521472)
25. Dmitrienko A, Molenberghs G, Chuang-Stein C, Offen O. Analysis of clinical trials using SAS, ed 1. Cary, NC: SAS Institute; 2005.
26. M.J. Barry, W.O. Williford, and Y. Chang Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urology 154 1995 1770 1774
27. D. Behr-Roussel, S. Oger, and S. Caisey Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats Eur Urol 59 2011 272 279
28. J.H. Schagen van Leeuwen, R. Castro, M. Busse, and B.L.H. Bemelmans The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms Eur Urol 50 2006 440 453 (Pubitemid 44189071)
29. C.C. Carson, J. Rajfer, and I. Eardley The efficacy and safety of tadalafil: an update BJU Int 93 2004 1276 1281 (Pubitemid 38823952)
30. F. Montorsi, H.P. Nathan, and A. McCullough Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial J Urol 172 2004 1036 1041 (Pubitemid 39096457)
31. H. Porst, F. Giuliano, and S. Glina Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial Eur Urol 50 2006 351 359 (Pubitemid 44038075)
32. H. Porst, K.T. McVary, and F. Montorsi Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia Eur Urol 56 2009 727 736
33. M. Braun, G. Wassmer, T. Klotz, B. Reifenrath, M. Mathers, and U. Engelmann Epidemiology of erectile dysfunction: results of the "Cologne Male Survey." Int J Impot Res 12 2000 305 311 (Pubitemid 32175951)
34. R. Rosen, J. Altwein, and P. Boyle Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol 44 2003 637 649 (Pubitemid 37542920)
35. C.F. Donatucci, G.B. Brock, and E.R. Goldfischer Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study BJU Int 107 2011 1110 1116